Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Oct;68(4):720–726. doi: 10.1038/bjc.1993.417

The effect of recombinant human erythropoietin treatment on tumour radiosensitivity and cancer-associated anaemia in the mouse.

B Joiner 1, V K Hirst 1, S R McKeown 1, J J McAleer 1, D G Hirst 1
PMCID: PMC1968603  PMID: 8398699

Abstract

Recombinant human erythropoietin (rHuEpo) has recently become available for the treatment of chronic anaemia, including that associated with cancer. Carcinoma NT in CBA mice causes a progressive anaemia which can be overcome by daily injections of recombinant human erythropoietin (rHuEpo). This model was used to study the effect of haematocrit on tumour blood flow, growth rate and radiosensitivity, in mice with haematocrits ranging from approximately 38% (control) to 65% (20 U/day rHuEpo). Tumours showed a small but significant slowing in growth rate with higher haematocrit. In vitro studies showed rHuEpo had no direct effect on the growth of NT cells. Tumour blood flow was measured by two methods in each mouse (133Xe clearance and 86Rubidium uptake). Blood flow showed a tendency to decrease with increasing blood viscosity although this effect was not significant despite the large differences in haematocrit. Although tumour doubling time was prolonged despite the large differences in haematocrit. Although tumour doubling time was prolonged with increasing radiation dose, from 0 (sham irradiated) to 35 Gy, haematocrit was not found to influence the growth delay. This was attributed to adaptation of the tumour during the relatively slow change in the haematocrit. rHuEpo is being considered for clinical use in anaemic cancer patients. Our data suggest that this treatment will correct haematocrit with no effect on tumour radiosensitivity.

Full text

PDF
720

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boyd H. K., Lappin T. R. Erythropoietin deficiency in the anaemia of chronic disorders. Eur J Haematol. 1991 Apr;46(4):198–201. doi: 10.1111/j.1600-0609.1991.tb00540.x. [DOI] [PubMed] [Google Scholar]
  2. Dainiak N., Kulkarni V., Howard D., Kalmanti M., Dewey M. C., Hoffman R. Mechanisms of abnormal erythropoiesis in malignancy. Cancer. 1983 Mar 15;51(6):1101–1106. doi: 10.1002/1097-0142(19830315)51:6<1101::aid-cncr2820510622>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  3. Dische S. Radiotherapy and anaemia--the clinical experience. Radiother Oncol. 1991;20 (Suppl 1):35–40. doi: 10.1016/0167-8140(91)90184-i. [DOI] [PubMed] [Google Scholar]
  4. Hirst D. G. Anemia: a problem or an opportunity in radiotherapy? Int J Radiat Oncol Biol Phys. 1986 Nov;12(11):2009–2017. doi: 10.1016/0360-3016(86)90139-2. [DOI] [PubMed] [Google Scholar]
  5. Hirst D. G., Hazlehurst J. L., Brown J. M. Changes in misonidazole binding with hypoxic fraction in mouse tumors. Int J Radiat Oncol Biol Phys. 1985 Jul;11(7):1349–1355. doi: 10.1016/0360-3016(85)90251-2. [DOI] [PubMed] [Google Scholar]
  6. Hirst D. G., Hazlehurst J. L., Brown J. M. The effect of alterations in haematocrit on tumour sensitivity to X-rays. Int J Radiat Biol Relat Stud Phys Chem Med. 1984 Oct;46(4):345–354. doi: 10.1080/09553008414551521. [DOI] [PubMed] [Google Scholar]
  7. Hirst D. G., Wood P. J. The adaptive response of mouse tumours to anaemia and retransfusion. Int J Radiat Biol Relat Stud Phys Chem Med. 1987 Apr;51(4):597–609. doi: 10.1080/09553008414552131. [DOI] [PubMed] [Google Scholar]
  8. Kallman R. F., DeNardo G. L., Stasch M. J. Blood flow in irradiated mouse sarcoma as determined by the clearance of xenon-133. Cancer Res. 1972 Mar;32(3):483–490. [PubMed] [Google Scholar]
  9. Koong A. C., Hirst D. G. The influence of chronic anaemia on the radiosensitivity of two mouse tumours. Br J Cancer. 1991 Apr;63(4):499–502. doi: 10.1038/bjc.1991.119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ludwig H., Fritz E., Kotzmann H., Höcker P., Gisslinger H., Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med. 1990 Jun 14;322(24):1693–1699. doi: 10.1056/NEJM199006143222402. [DOI] [PubMed] [Google Scholar]
  11. Mac Manus M. P., Elder G. E., Abram W. P., Bridges J. M. Effect of recombinant human erythropoietin on anemia caused by a murine mammary carcinoma. Exp Hematol. 1990 Aug;18(7):848–852. [PubMed] [Google Scholar]
  12. Miller C. B., Jones R. J., Piantadosi S., Abeloff M. D., Spivak J. L. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990 Jun 14;322(24):1689–1692. doi: 10.1056/NEJM199006143222401. [DOI] [PubMed] [Google Scholar]
  13. Miller C. B., Platanias L. C., Mills S. R., Zahurak M. L., Ratain M. J., Ettinger D. S., Jones R. J. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst. 1992 Jan 15;84(2):98–103. doi: 10.1093/jnci/84.2.98. [DOI] [PubMed] [Google Scholar]
  14. Oster W., Herrmann F., Gamm H., Zeile G., Lindemann A., Müller G., Brune T., Kraemer H. P., Mertelsmann R. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol. 1990 Jun;8(6):956–962. doi: 10.1200/JCO.1990.8.6.956. [DOI] [PubMed] [Google Scholar]
  15. Overgaard J., Hansen H. S., Jørgensen K., Hjelm Hansen M. Primary radiotherapy of larynx and pharynx carcinoma--an analysis of some factors influencing local control and survival. Int J Radiat Oncol Biol Phys. 1986 Apr;12(4):515–521. doi: 10.1016/0360-3016(86)90058-1. [DOI] [PubMed] [Google Scholar]
  16. Overgaard J. Sensitization of hypoxic tumour cells--clinical experience. Int J Radiat Biol. 1989 Nov;56(5):801–811. doi: 10.1080/09553008914552081. [DOI] [PubMed] [Google Scholar]
  17. Rojas A., Stewart F. A., Smith K. A., Soranson J. A., Randhawa V. S., Stratford M. R., Denekamp J. Effect of anemia on tumor radiosensitivity under normo and hyperbaric conditions. Int J Radiat Oncol Biol Phys. 1987 Nov;13(11):1681–1689. doi: 10.1016/0360-3016(87)90165-9. [DOI] [PubMed] [Google Scholar]
  18. SAPIRSTEIN L. A. Regional blood flow by fractional distribution of indicators. Am J Physiol. 1958 Apr;193(1):161–168. doi: 10.1152/ajplegacy.1958.193.1.161. [DOI] [PubMed] [Google Scholar]
  19. Schreuder W. O., Ting W. C., Smith S., Jacobs A. Testosterone, erythropoietin and anaemia in patients with disseminated bronchial cancer. Br J Haematol. 1984 Jul;57(3):521–526. doi: 10.1111/j.1365-2141.1984.tb02926.x. [DOI] [PubMed] [Google Scholar]
  20. Sevick E. M., Jain R. K. Viscous resistance to blood flow in solid tumors: effect of hematocrit on intratumor blood viscosity. Cancer Res. 1989 Jul 1;49(13):3513–3519. [PubMed] [Google Scholar]
  21. Taylor J., Mactier R. A., Stewart W. K., Henderson I. S. Effect of erythropoietin on anaemia in patients with myeloma receiving haemodialysis. BMJ. 1990 Sep 8;301(6750):476–477. doi: 10.1136/bmj.301.6750.476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Winearls C. G. Treatment of the anaemia of chronic renal failure with recombinant human erythropoietin. Drugs. 1989 Sep;38(3):342–345. doi: 10.2165/00003495-198938030-00002. [DOI] [PubMed] [Google Scholar]
  23. Zanelli G. D., Lucas P. B. Letter: Effect of stress on blood perfusion and vascular space in transplanted mouse tumours. Br J Radiol. 1976 Apr;49(580):382–384. doi: 10.1259/0007-1285-49-580-382. [DOI] [PubMed] [Google Scholar]
  24. Zucker S. Anemia in cancer. Cancer Invest. 1985;3(3):249–260. doi: 10.3109/07357908509039786. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES